Pharmafile Logo
Pharmafocus logo
Advanced Search

HIV

Showing 15 posts of 200 posts found.

HIV infected cell

ViiV and Janssen to test new HIV regimen in Phase III trial

January 7, 2016
Manufacturing and Production, Medical Communications, Research and Development Edurant, HIV, Janssen, ViiV Healthcare, cabotegravir, collaboration, phase III, rilpivirine

Janssen has formalised its collaboration with ViiV Healthcare on the Phase III development and commercialisation of a two-drug regimen to …

News
ian_green

Terrence Higgins Trust announces new CEO

January 6, 2016
Medical Communications AIDS, HIV, Terrance Higgins Trust

Leading UK-based HIV and sexual health charity The Terrence Higgins Trust has announced the appointment of Ian Green as the …

Appointment
landing-hero-images1

ViiV Healthcare to acquire Bristol-Myers Squibb’s HIV pipeline drugs

December 18, 2015
Medical Communications, Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, HIV, ViiV, ViiV Healthcare

Specialist HIV company ViiV Healthcare has agreed deals worth up to $1.46 billion to purchase Bristol-Myers Squibb’s late stage HIV …

News
janssen_scientists

J&J announces new partnerships in fight against HIV/AIDS

December 1, 2015
Research and Development AIDS, HIV, Janssen

Johnson &Johnson is entering four new public-private partnerships aimed at significantly reducing the burden of HIV incidence among young girls …

News
Medicines Patent Pool

Collaboration between MPP and University of Liverpool targets HIV nanomedicines

December 1, 2015
Manufacturing and Production, Research and Development AIDS, HIV, Medicines Patent Pool, antiretrovirals, nanomedicines

The Medicines Patent Pool (MPP) and the University of Liverpool have agreed a partnership to use the university’s solid drug …

News
Gilead image

EU approval for Gilead’s HIV combo Genvoya

December 1, 2015
Manufacturing and Production, Sales and Marketing European Commission, Genvoya, Gilead, Gilead Sciences, HIV, TDF, World Aids Day, european union, taf

Gilead Sciences has won marketing authorisation from the European Commission (EC) for the once-daily single tablet regimen Genvoya as an …

News
EU flag

European Commission funds €23m project to develop HIV vaccine

November 2, 2015
Research and Development, Sales and Marketing BioNTech, European Commission, HIV, R&D, horizon 2020

The European Commission has kicked-off a new €23 million research program to bring together researchers to work on a potential …

News
gilead-sciences

Gilead presents Phase III results for Genvoya in HIV

October 22, 2015
Medical Communications, Research and Development Genvoya, Gilead Sciences, HIV

Gilead Sciences has today announced 96-week results from two Phase III studies evaluating its investigational once-daily single tablet regimen (STR), …

News
Michel Sidibe

UN calls on pharma industry to make medicines more affordable

September 29, 2015
Manufacturing and Production AIDS, HIV, Michel Sidibe, UNAIDS, United Nations, antiretroviral treatments

The United Nations AIDS agency, UNAIDS, has called on governments and the pharmaceutical industry to ensure that medicines remain accessible …

News
HIV infected cell

ViiV in late-stage HIV trial success

September 23, 2015
Research and Development HIV, Triumeq, ViiV, virology

Switching patients to Triumeq, a once-daily combination treatment for HIV, is as effective as remaining on antiretroviral therapy in certain …

News
Truvada pill

Gilead’s Truvada prevents HIV infections in high-risk men

September 10, 2015
Research and Development Gilead, HIV, PrEP, Truvada, pre-exposure prophylaxis treatment, sexually transmitted infections

UK researchers say Truvada, Gilead’s HIV prevention treatment, should be added to the country’s ‘HIV prevention toolkit’, after a study …

News
GSK image

GSK launches new HIV research centre

May 11, 2015
Research and Development, Sales and Marketing AIDS, GSK, HIV, UNC-Chapel Hill, ViiV, qura

GlaxoSmithKline is boosting its philanthropic efforts in R&D into HIV/AIDS by teaming up with academic researchers to launch a new …

News
ViiV founder Dr Manuel Goncalves

Reputation gains from focussing on the patient

May 11, 2015
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing GSK, HIV, Manuel Goncalves, Pfizer, ViiV

Since being spun-off from GSK and Pfizer, specialist HIV firm ViiV Healthcare has earned the best corporate reputation amongst patients …

Feature
GSK image

Generics continue to erode GSK sales

May 6, 2015
Sales and Marketing GSK, HIV, Novartis, Q1, ViiV, Witty, hampton, respiratory

GlaxoSmithKline’s pharma sales continued to slide in the first quarter of 2015, but ViiV healthcare and the portfolios acquired from …

News
Gilead image

Gilead’s next-generation HIV drug to be FDA assessed

April 8, 2015
Research and Development, Sales and Marketing F/TAF, FDA, Gilead, HIV, Tenofovir Alafenamide, emtricitabine

Gilead Sciences has filed its second new drug application for a new combination HIV treatment with the FDA.The California-based company …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025